120 Participants Needed

Axatilimab + Ruxolitinib for Graft-versus-Host Disease

Recruiting at 82 trial locations
IC
IC
Overseen ByIncyte Corporation Call Center (ex-US)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have received systemic corticosteroids or started certain treatments like CNIs or mTOR inhibitors within 2 weeks before the trial begins, and you must not have used a JAK inhibitor within 8 weeks before joining.

What data supports the effectiveness of the drug Axatilimab + Ruxolitinib for Graft-versus-Host Disease?

Ruxolitinib, a component of the treatment, is approved for chronic graft-versus-host disease and has shown effectiveness in both acute and chronic forms of the condition, especially in patients who do not respond to steroids.12345

Is the combination of Axatilimab and Ruxolitinib safe for treating graft-versus-host disease?

Ruxolitinib, used for treating graft-versus-host disease, has been generally well-tolerated in patients, though some have experienced serious side effects like infections and respiratory issues. Safety data from various studies suggest it is generally safe, but patients should be aware of potential risks.12678

What makes the drug Axatilimab + Ruxolitinib unique for treating graft-versus-host disease?

This treatment combines Axatilimab, a novel drug, with Ruxolitinib, a JAK1/2 inhibitor that has shown effectiveness in treating graft-versus-host disease by targeting specific pathways involved in the immune response. This combination may offer a new approach for patients who do not respond to standard treatments like corticosteroids.12349

What is the purpose of this trial?

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Research Team

IM

Incyte Medical Monitor

Principal Investigator

Incyte Corporation

Eligibility Criteria

This trial is for individuals aged 12 or older who have been newly diagnosed with moderate to severe chronic Graft-Versus-Host Disease (cGVHD) and need systemic therapy. They should not be dependent on platelet transfusions, have a certain level of white blood cells and platelets, and must commit to preventing pregnancy or fathering children.

Inclusion Criteria

Willingness to avoid pregnancy or fathering children
I have had one stem cell transplant from any donor.
I have a new severe reaction from a transplant that needs treatment.
See 2 more

Exclusion Criteria

My blood cancer has returned or I've been treated for a comeback after a stem cell transplant.
I have had more than one stem cell transplant from a donor.
Pregnant or breastfeeding
See 11 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive axatilimab in combination with ruxolitinib or corticosteroids alone

6 months
Regular visits as per protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 2 years and 30 days

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • Axatilimab
  • Corticosteroids
  • Ruxolitinib
Trial Overview The study tests the safety and effectiveness of Axatilimab in combination with Ruxolitinib compared to standard treatments like corticosteroids for cGVHD. It aims to see if adding Axatilimab improves treatment outcomes.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Treatment Group CExperimental Treatment1 Intervention
Corticosteroids alone will be administered at a protocol defined starting dose.
Group II: Treatment Group BExperimental Treatment1 Intervention
Ruxolitinib will be administered at a protocol defined starting dose.
Group III: Treatment Group AExperimental Treatment2 Interventions
Axatilimab will be administered at a protocol defined starting dose plus ruxolitinib at a protocol defined starting dose.

Axatilimab is already approved in United States for the following indications:

🇺🇸
Approved in United States as Axatilimab for:
  • Chronic Graft-Versus-Host Disease

Find a Clinic Near You

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials
408
Recruited
66,800+
Steven Stein profile image

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot profile image

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Findings from Research

Ruxolitinib (Jakafi) has received approval for the treatment of chronic graft-vs-host disease, indicating its efficacy in managing this condition.
The approval of ruxolitinib highlights its role as a kinase inhibitor, which works by targeting specific pathways involved in the immune response, potentially improving patient outcomes.
New Indication for Ruxolitinib.Aschenbrenner, DS.[2023]
Ruxolitinib prophylaxis showed a 41.2% incidence of acute graft-versus-host disease (aGVHD) in patients after modified donor lymphocyte infusion, indicating it can help reduce the severity of aGVHD in high-risk leukemia patients post-transplant.
Among the 17 patients studied, 58.8% achieved a complete response, suggesting that ruxolitinib may effectively maintain the graft-versus-leukemia (GVL) effect while managing aGVHD, despite a median follow-up of only 8 months.
Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.Tang, Y., Yang, D., Xie, R., et al.[2023]
In a study of 8 patients with acute or chronic graft versus host disease (GVHD) who were unresponsive to standard treatments, ruxolitinib demonstrated a high overall response rate of 85%, with 50% achieving complete response.
Ruxolitinib was well-tolerated, indicating it could be a promising rescue therapy for patients suffering from refractory GVHD.
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Sarmiento Maldonado, M., Ramírez Villanueva, P., Bertín Cortes-Monroy, P., et al.[2022]

References

New Indication for Ruxolitinib. [2023]
Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion. [2023]
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis. [2022]
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. [2023]
Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC. [2021]
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. [2021]
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial. [2022]
Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. [2022]
Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security